Brief: Windtree Advances Lower Cost Manufacturing Of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel
26/06/2025 22:15
June 26 (Reuters) - Windtree Therapeutics Inc WINT.O: WINDTREE ADVANCES LOWER COST MANUFACTURING OF PHEXXI, EVOFEM’S HORMONE-FREE, ON-DEMAND PRESCRIPTION CONTRACEPTIVE GEL WINDTREE THERAPEUTICS: CONTRACT INKED WITH OUTSIDE U.S MANUFACTURER TO CUT PHEXXI MANUFACTURING COSTS BY OVER 50% BY END OF 2026 WINDTREE THERAPEUTICS INC: TECH TRANSFER UNDERWAY WITH VALIDATION BATCH MANUFACTURING EXPECTED TO BEGIN IN 2026 Source text: ID:nGNX21CYlX Further company coverage: WINT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Windtree Therapeutics
See all newsBrief: Windtree Therapeutics Announces It Has Signed A Letter Of Intent To Acquire Commloan
Brief: Windtree Therapeutics Announces It May Receive License Agreement Payments From Its Licensee For Renewed Acute Pulmonary Development By The Licensee
Brief: Windtree Therapeutics Stockholders Approve Key Proposals For Revenue And Profit Generation At The Special Stockholder Meeting
Brief: Windtree Therapeutics Terminates Seismic-C Clinical Study At 20 Enrollments - SEC Filing
Brief: Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study